Novartis Unveils Positive Phase II Results For Genetic Auto-inflammatory Disease Candidate
Interleukin 1b blocker ACZ885 achieves complete clinical remission in seven days for Cryopyrin-Associated Periodic Syndrome Patients.
Interleukin 1b blocker ACZ885 achieves complete clinical remission in seven days for Cryopyrin-Associated Periodic Syndrome Patients.